Rutas metabólicas intracelulares que intervienen en el desarrollo tumoral en pacientes con síndrome metabólico

Christian Daniel  Calonge-Solano; Gustavo Elías  De La Hoz-Herrera; María Juliana  Castilla-Velásquez

doi:10.18041/2390-0512/biociencias.2.10694

Autores/as

Christian Daniel Calonge-Solano Universidad Libre-Seccional Barranquilla https://orcid.org/0000-0002-1339-0816
Gustavo Elías De La Hoz-Herrera Universidad Libre-Seccional Barranquilla https://orcid.org/0000-0002-5296-4333
María Juliana Castilla-Velásquez Universidad del Sinú Elías Bechara Zainum-Seccional Cartagena https://orcid.org/0000-0002-5076-205X

DOI:

https://doi.org/10.18041/2390-0512/biociencias.2.10694

Palabras clave:

Síndrome metabólico, Obesidad, Cáncer, Adiponectina, Leptina, IGF-1

Referencias

Gil JC, Loredo L De, Ramos DO, Lúquez H, Piña C, Bruce HG, et al. Consenso Latinoamericano de la Asociación Latinoamericana de Diabetes ( ALAD ) Epidemiología , Diagnóstico , Control , Prevención y Tratamiento del Síndrome Metabólico en Adultos. 2010;18(1):25–44.

Secretan BL, Ph D, Scoccianti C, Ph D, Loomis D, Ph D. Body Fatness and Cancer — Viewpoint of the IARC Working Group. N Engl J Med. 2016;375(8):794–8.

2008-2013 Action Plan for the Global Strategy for the Prevention and Control of Noncommunicable Diseases The six objectives of the 2008-2013 Action Plan are : 2013;

Rojas Concepción AA, Guerra González Y, Guerra Chagime R, Sánchez Alvarez de la Campa AI, Moreno Corominas Y. Factores de riesgo del síndrome metabólico en adolescentes de San Juan y Martínez. Rev Ciencias Médicas Pinar del Río. 2020;24(2):178–85.

Arrunátegui-Correa V. Despistaje de diabetes mellitus tipo 2 en una población adulta urbana del distrito de Coishco, Ancash, Perú. Rev Medica Hered. 2015;26(3):173.

Ortega FB, Lavie CJ, Blair SN. Obesity and cardiovascular disease. Circ Res. 2016;118(11):1752–70.

Rousseau MC, Parent MÉ, Pollak MN, Siemiatycki J. Diabetes mellitus and cancer risk in a population-based case-control study among men from Montreal, Canada. Int J Cancer. 2006;118(8):2105–9.

Giovannucci E, Harlan DM, Archer MC, Bergenstal RM, Gapstur SM, Habel LA, et al. Diabetes and cancer: A consensus report. Diabetes Care. 2010;33(7):1674–85.

Suba Z. Interplay between insulin resistance and estrogen deficiency as co-activators in carcinogenesis. Pathol Oncol Res. 2012;18(2):123–33.

Eketunde AO. Diabetes as a Risk Factor for Breast Cancer. Cureus. 2020;12(5):10–3.

Isabel V. La ilustración científica: Una necesidad para favorecer la divulgación científica en redes sociales. 2021;(April).

Mathers CD, Loncar D. Projections of global mortality and burden of disease from 2002 to 2030. PLoS Med. 2006;3(11):2011–30.

Vera A, Hernández B, Ramírez L, Campos F, Becerra L. Documento guía Alimentación saludable. Aliment Saludab [Internet]. 2013;45. Available from: https://www.minsalud.gov.co/sites/rid/Lists/BibliotecaDigital/RIDE/VS/PP/SNA/Guia-Alimentacion-saludable.pdf

Rivas-Castro A, Leguísamo-Peñate I, Puello-Viloria Y. Estilo de vida en pacientes con Diabetes Mellitus tipo II de una institución de salud en Santa Marta, Colombia, 2017. Duazary. 2020;17(4):55–64.

Duque et al. Revista Colombiana de Revista Colombiana de. Rev Colomb Cancerol [Internet]. 2011;17(2):642–7. Available from: http://www.redalyc.org/articulo.oa?id=80401303%0Ahttp://www.scielo.org.co/scielo.php?script=sci_arttext&pid=S0034-74502014000200002%0Ahttp://www.redalyc.org/articulo.oa?id=355534449002%0Ahttps://www.elsevier.es/es-revista-revista-colombiana-cancerologia-3

Bray F, Ferlay J, Laversanne M, Brewster DH, Gombe Mbalawa C, Kohler B, et al. Cancer Incidence in Five Continents: Inclusion criteria, highlights from Volume X and the global status of cancer registration. Int J Cancer. 2015;137(9):2060–71.

Mejía W, Castro C, Umaña A, de Castro C, Riveros T, Sánchez-Gómez M. Insulin-like growth factor receptor I signaling in a breast cancer cell line. Biomedica. 2010;30(4):551–8.

Seidell JC. Epidemiology - Definition and Classification of Obesity. Clin Obes Adults Child. 2007;23(2):1–11.

Wang YC, McPherson K, Marsh T, Gortmaker SL, Brown M. Health and economic burden of the projected obesity trends in the USA and the UK. Lancet [Internet]. 2011;378(9793):815–25. Available from: http://dx.doi.org/10.1016/S0140-6736(11)60814-3

Swinburn BA, Sacks G, Hall KD, McPherson K, Finegood DT, Moodie ML, et al. The global obesity pandemic: Shaped by global drivers and local environments. Lancet [Internet]. 2011;378(9793):804–14. Available from: http://dx.doi.org/10.1016/S0140-6736(11)60813-1

Keaver L, Webber L, Dee A, Shiely F, Marsh T, Balanda K, et al. Application of the UK foresight obesity model in Ireland: The health and economic consequences of projected obesity trends in Ireland. PLoS One. 2013;8(11):1–8.

Carvajal C. Tejido adiposo, Obesidad e Insulinoresistencia. Med Leg costa rica. 2015;32(2).

Manzur F, Alvear C, Alayón AN. Adipocitos, obesidad visceral, inflamación y enfermedad cardiovascular. Rev Colomb Cardiol [Internet]. 2010;17(5):207–13. Available from: http://dx.doi.org/10.1016/S0120-5633(10)70243-6

Dalamaga M, Diakopoulos KN, Mantzoros CS. The role of adiponectin in cancer: A review of current evidence. Endocr Rev. 2012;33(4):547–94.

Lopez Guzmán C de jesus. Asociación genética con indicadores de síndrome metabólico en adolescentes sedentarios con sobrepeso. Rev Mex Investig en Cult Física y Deport [Internet]. 2018;8(10):2–16. Available from: http://revista.ened.edu.mx/index.php/revistaconade/article/view/161

Marcos A, Nova E, Montero A. Changes in the immune system are conditioned by nutrition. Eur J Clin Nutr. 2003;57:S66–9.

Ahima RS, Flier JS. Adipose tissue as an endocrine organ. Trends Endocrinol Metab. 2000;11(8):327–32.

Muñoz M, Mazure RA, Culebras JM. Obesity and the immune system. Nutr Hosp. 2004;19(6):319–24.

Coelho M, Oliveira T, Fernandes R. Biochemistry of adipose tissue: An endocrine organ. Arch Med Sci. 2013;9(2):191–200.

Trayhurn P, Beattie JH. Physiological role of adipose tissue: white adipose tissue as an endocrine and secretory organ. Proc Nutr Soc. 2001;60(3):329–39.

Esser N, Legrand-Poels S, Piette J, Scheen AJ, Paquot N. Inflammation as a link between obesity, metabolic syndrome and type 2 diabetes. Diabetes Res Clin Pract. 2014;105(2):141–50.

Makki K, Froguel P, Wolowczuk I. Adipose Tissue in Obesity-Related Inflammation and Insulin Resistance: Cells, Cytokines, and Chemokines. ISRN Inflamm. 2013;2013:1–12.

Kanneganti TD, Dixit VD. Immunological complications of obesity. Nat Immunol [Internet]. 2012;13(8):707–12. Available from: http://dx.doi.org/10.1038/ni.2343

Kammoun HL, Kraakman MJ, Febbraio MA. Adipose tissue inflammation in glucose metabolism. Rev Endocr Metab Disord. 2014;15(1):31–44.

Álvarez-Castro P, Sangiao-Alvarellos S, Brandón-Sandá I, Cordido F. Funcion endocrina en la obesidad. Endocrinol y Nutr. 2011;58(8):422–32.

Costa B, Cabré JJ, Martín F. Síndrome metabólico, resistencia a la insulina y diabetes. ¿Qué se oculta bajo la punta del iceberg? Atención Primaria [Internet]. 2003;31(7):436–45. Available from: http://dx.doi.org/10.1016/S0212-6567(03)79204-X

G MT, María A, Hematología S, Central L, Oncología I De, Roffo A, et al. Sobrepeso , obesidad y síndrome metabólico . Estado de situación del paciente oncológico en nuestro medio. 84(1):13–8.

Uzunlulu M, Telci Caklili O, Oguz A. Association between Metabolic Syndrome and Cancer. Ann Nutr Metab. 2016;68(3):173–9.

Russo A, Autelitano M, Bisanti L. Metabolic syndrome and cancer risk. Eur J Cancer. 2008;44(2):293–7.

Esposito K, Chiodini P, Colao A, Lenzi A, Giugliano D. Metabolic syndrome and risk of cancer: A systematic review and meta-analysis. Diabetes Care. 2012;35(11):2402–11.

Siegel RL, Miller KD, Jemal A. Cancer statistics, 2020. CA Cancer J Clin. 2020;70(1):7–30.

Gallagher EJ, LeRoith D, Karnieli E. The Metabolic Syndrome-from Insulin Resistance to Obesity and Diabetes. Med Clin North Am [Internet]. 2011;95(5):855–73. Available from: http://dx.doi.org/10.1016/j.mcna.2011.06.001

Larsson SC, Mantzoros CS, Wolk A. Diabetes mellitus and risk of breast cancer: A meta-analysis. Int J Cancer. 2007;121(4):856–62.

Campbell PT, Jacobs EJ, Newton CC, Gapstur SM, Patel A V. Diabetes and cause-specific mortality in a prospective cohort of one million U.S. adults. Diabetes Care. 2012;35(9):1835–44.

Harding JL, Shaw JE, Peeters A, Cartensen B, Magliano DJ. Cancer risk among people with type 1 and type 2 diabetes: Disentangling true associations, detection bias, and reverse causation. Diabetes Care. 2015;38(2):264–70.

Song S, Wang B, Zhang X, Hao L, Hu X, Li Z, et al. Long-term diabetes mellitus is associated with an increased risk of pancreatic cancer: A meta-analysis. PLoS One. 2015;10(7):1–27.

Wang C, Wang X, Gong G, Ben Q, Qiu W, Chen Y, et al. Increased risk of hepatocellular carcinoma in patients with diabetes mellitus: A systematic review and meta-analysis of cohort studies. Int J Cancer. 2012;130(7):1639–48.

Keaney JF, Larson MG, Vasan RS, Wilson PWF, Lipinska I, Corey D, et al. Obesity and systemic oxidative stress: Clinical correlates of oxidative stress in the Framingham study. Arterioscler Thromb Vasc Biol. 2003;23(3):434–9.

Yu H, Berkel H. Insulin-like growth factors and cancer. J La State Med Soc. 1999;151(4):218–23.

Gunter MJ, Hoover DR, Yu H, Wassertheil-Smoller S, Rohan TE, Manson JE, et al. Insulin, insulin-like growth factor-I, and risk of breast cancer in postmenopausal women. J Natl Cancer Inst. 2009;101(1):48–60.

Andò S, Gelsomino L, Panza S, Giordano C, Bonofiglio D, Barone I, et al. Obesity, leptin and breast cancer: Epidemiological evidence and proposed mechanisms. Cancers (Basel). 2019;11(1):1–27.

Naimo GD, Gelsomino L, Catalano S, Mauro L, Andò S. Interfering Role of ERα on Adiponectin Action in Breast Cancer. Front Endocrinol (Lausanne). 2020;11(February):1–10.

Mauro L, Naimo GD, Gelsomino L, Malivindi R, Bruno L, Pellegrino M, et al. Uncoupling effects of estrogen receptor a on LKB1/AMPK interaction upon adiponectin exposure in breast cancer. FASEB J. 2018;32(8):4343–55.

Horst D, Chen J, Morikawa T, Ogino S, Kirchner T, Shivdasani RA. Differential WNT activity in colorectal cancer confers limited tumorigenic potential and is regulated by MAPK signaling. Cancer Res. 2012;72(6):1547–56.

Müller CB, De Bastiani MA, Becker M, França FS, Branco MA, Alves Castro MA, et al. Potential crosstalk between cofilin-1 and EGFR pathways in cisplatin resistance of non-small-cell lung cancer. Oncotarget. 2015;6(6):3531–9.

Lo CW, Chen MW, Hsiao M, Wang S, Chen CA, Hsiao SM, et al. IL-6 trans-signaling in formation and progression of malignant ascites in ovarian cancer. Cancer Res. 2011;71(2):424–34.

Riondino S, Roselli M, Palmirotta R, Della-Morte D, Ferroni P, Guadagni F. Obesity and colorectal cancer: Role of adipokines in tumor initiation and progression. World Journal of Gastroenterology. 2014;20(18):5177–90.

Roslan NH, Makpol S, Mohd Yusof YA. A review on dietary intervention in obesity associated colon cancer. Asian Pacific Journal of Cancer Prevention. 2019;20(5):1309–19.

Waldner MJ, Foersch S, Neurath MF. Interleukin-6 - A key regulator of colorectal cancer development. Int J Biol Sci. 2012;8(9):1248–53.

Rutas metabólicas intracelulares que intervienen en el desarrollo tumoral en pacientes con síndrome metabólico

Autores/as

DOI:

Palabras clave:

Resumen

Descargas

Biografía del autor/a

Referencias

Descargas

Publicado

Número

Sección

Licencia

Cómo citar

Enviar un artículo

Información

Idioma

Palabras clave